Kolexia
Naman Herve Oncologie médicale
Naman Herve
Oncologie médicale
Hp A. Tzanck Mougins Sophia Antipolis
Mougins, France
61 Activités
184 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Cellules tumorales circulantes Éosinophilie Tumeurs de la prostate Myélome multiple Infections à staphylocoques Métastase tumorale Récidive tumorale locale Prédisposition génétique à une maladie

Collaborateurs

Voir plus
Largillier Remy
Largillier Remy
Hp A. Tzanck Mougins Sophia Antipolis, Mougins, France
Braccini Antoine
Braccini Antoine
Hp A. Tzanck Mougins Sophia Antipolis, Mougins, France
Kreitmann Thomas
Kreitmann Thomas
Hp A. Tzanck Mougins Sophia Antipolis, Mougins, France
Gross Rudolph
Gross Rudolph
Clinique Soins Suite Readapt St Basile, Mougins, France

Industries

Voir plus
Novartis
4 collaboration(s)
Dernière en 2019
Servier
4 collaboration(s)
Dernière en 2019
AstraZeneca
4 collaboration(s)
Dernière en 2019
Amgen
2 collaboration(s)
Dernière en 2019

Dernières activités

Voir plus
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.
JAMA oncology   10 mars 2022
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.
Leukemia   09 avril 2019
Utilisation et besoin des patients en soins de support au cours de la prise en charge du cancer du poumon
23e Congrès de Pneumologie de Langue Française   01 janvier 2019
Supportive care: Patient expectations, availability and uptake
Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany   01 octobre 2018
Roadmap for supportive care according to patients' perspectives.
2018 ASCO Annual Meeting I   01 juin 2018
Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers: Randomized Trial to Evaluate the Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers.
Essai Clinique (Institut Curie)   06 avril 2018
First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
Maintaining professional activity during breast cancer treatment.
European journal of cancer care   18 février 2016
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
The oncologist   25 juin 2015
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Leukemia & lymphoma   20 février 2015